Drug Approval | March 01, 2022
USFDA approves CITI Biopharma’s Vonjo
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
110 BDS graduates admitted in week one of the launch
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
Subscribe To Our Newsletter & Stay Updated
